Head-to-head · free

MannKind vs Nektar Therapeutics

MNKD vs NKTR — return on capital, cash generation, margins and balance sheet side by side.

MNKD

6 / 8

measures where MNKD leads

NKTR

2 / 8

measures where NKTR leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureMNKD · FY2025NKTR · FY2025
Revenue$349.0M$55.2M
Net income$5.9M(164.1M)
Revenue growth (yearly, multi-year)46.7%23.6%
Free cash flow$13.7M(208.7M)
Free cash flow margin3.9%-377.8%
Net cash / (debt)——
ROIC——
Return on equity—-217.9%
Gross margin74.8%100.0%
Operating margin13.3%-236.8%
Net debt / EBITDA5.48x0.11x

Figures are as reported by each company; latest fiscal year shown.

Where MannKind's cash went (FY2025)

Capital spending
$4.6M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MNKD profile →

Where Nektar Therapeutics's cash went (FY2025)

Capital spending
$171000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NKTR profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons